Founded in 2013, YAFO Capital is a Shanghai based boutique investment and advisory firm, with professional team in our China, U.S., and London offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. YAFO has been ranked as the No. 1 advisor for China cross border licensing transactions in the past three years.
Staatz Business Development & Strategy
Founded in 2006, Staatz Consulting is a strategic and operational partner in Business Development and Market Access consulting, working with a broad client basis from the international (USA, Europe, Asia) biotechnology, pharmaceutical, medtech and investment industry. We provide Transaction Advisory Services on the sell and the buy side. Our track-record of transactions comprises all customary agreement types and geographies (global, regional, local) in a broad variety of indication areas with a head-line value exceeding US$ 4.5 bn in total to date. Our success is based on our experienced senior consultants with more than 25 years industry experience each. We benefit from our wide industry network, thorough preparation, efficient and structured operational management and skilled negotiation. Our Market Access team provides strategic and operative Market Access expertise predominantly for Europe combining scientific capabilities with a deep knowledge of payer decision frameworks as well as Health Technology Assessment (HTA) processes. We cover all developmental stages in a broad range of indications. We excel in the thorough assessment of the competitive and HTA landscape, the development of compelling value positions for your product, evidence guidance matching payer expectations, clinical trial design for HTA purposes, payer research and Early Scientific HTA advice, as well as successful Market Access operations including value, JCA and HTA dossiers and payer negotiations.
Propharma
At ProPharma, we help pharmaceutical, biotechnology, and medical device companies bring life-changing therapies to market. From early development through clinical, regulatory approval, and commercialization, we provide expert guidance to navigate complex challenges and accelerate success. Our mission is simple – improving patient health and safety by delivering the highest quality regulatory, compliance, clinical research, pharmacovigilance, and medical information services throughout the entire product lifecycle. | For over 25 years, ProPharma has partnered with biotech, pharmaceutical, and medical device organizations to bring groundbreaking therapies to market. Offering a fully customizable, end-to-end suite of services, we empower our clients to overcome regulatory complexities and deliver life-changing therapies to patients worldwide. At ProPharma, we help pharmaceutical, biotechnology, and medical device companies bring life-changing therapies to market. From early development through clinical, regulatory approval, and commercialization, we provide expert guidance to navigate complex challenges and accelerate success. Our mission is simple – improving patient health and safety by delivering the highest quality regulatory, compliance, clinical research, pharmacovigilance, and medical information services throughout the entire product lifecycle.
Mexico Pavilion (MEX BIO)
MEX BIO Pavilion – BIO International Convention 2026 The MEX BIO Pavilion represents Mexico’s coordinated national presence at the BIO International Convention, the world’s leading global event for biotechnology and life sciences. Since 2022, Mexico has maintained a continuous and growing participation at BIO through a national pavilion, reflecting the strategic importance of the life sciences sector for the country and the sustained collaboration between industry, government, academia, and innovation stakeholders. MEX BIO serves as a platform for international engagement, business development, and ecosystem positioning, bringing together Mexican pharmaceutical and biotechnology companies, CROs and CDMOs, startups, research institutions, clusters, and public agencies. Over the past four editions, more than 50 Mexican organizations have participated, positioning Mexico as a key life sciences hub in Latin America and a reliable partner for global collaboration. The Pavilion is designed to go beyond a traditional exhibition space. Through a curated program of activities—including MEX BIO Day, MEX BIO Talks, MEX BIO Walks, and high-level institutional engagements—the Pavilion facilitates targeted meetings, strategic dialogues, and direct interaction with international partners, investors, and decision-makers. A dedicated digital platform and ecosystem wall further enhance visibility and extend engagement before, during, and after the Convention. Mexico’s presence at BIO reflects the country’s commitment to innovation, advanced manufacturing, regulatory dialogue, and international cooperation in life sciences. The MEX BIO Pavilion offers global stakeholders a unique entry point to explore Mexico’s capabilities, connect with its innovation ecosystem, and identify opportunities for collaboration, investment, and market access in one of the region’s most dynamic life sciences environments.
Insilico Medicine
We are an end-to-end, artificial intelligence-driven pharma-technology company with a mission to accelerate drug discovery and development by leveraging our rapidly evolving, proprietary platform across biology, chemistry, and clinical development. Our Pharma.AI platform has the potential to rapidly bring novel breakthrough medicines to patients while decreasing costs and increasing probabilities of success. | Insilico Medicine is a leading generative AI-driven biotech company. Our mission is to accelerate drug discovery and development by leveraging our robust Pharma.AI platform across biology, chemistry and clinical development. With 31 programs in development including 5 clinical stage assets, our generative AI platform helps us advance the pipeline of novel drug candidates rapidly and effectively in oncology, immunology, anemia, fibrosis, COVID and others. We are actively looking for asset out-licensing and strategic biopharma partners to develop successful drugs together to help patients. In addition we have a suite of AI software tools that can be licensed for drug discovery. | We are a globally leading end-to-end generative AI-driven biotech company in terms of AIDD pipeline progress, with a mission to accelerate drug discovery and development by leveraging our rapidly evolving, proprietary Pharma.AI platform across biology, chemistry and clinical development. Our generative AI platform helps us to rapidly and efficiently advance our fully self-generated AIDD pipeline primarily composed of novel drug candidates.
HANS Scientific
HANS Scientific is your nimble partner for CMO and WFI Generation. Our on-staff engineering and regulatory teams enable us to ramp projects quickly and with flexibility to meet your requirements. We are an agile, US-Based CMO with aseptic Fill/Finish and ALUS Lyophilization chamber. Highly innovative WFI generation equipment designed/built in the US, and bulk WFI in Bioprocess containers are readily available.
GlobalData
GlobalData has decades of experience in being the trusted, gold standard intelligence provider to leading Pharmaceutical brands, manufacturers, and suppliers, helping them to make faster, more informed decisions. | GlobalData is a data and analytics company providing the Life Science Community with Market and Competitive Intelligence. GlobalData serves over 4,000 world’s largest companies with over 600 healthcare analysts by gaining insights into competitors, evaluating market opportunities, and provide strategic opinions in the Pharma/Biotech, CMO/CDMO, CRO, Medical Device/Medtech and Consumer Health industries. From research and development, clinical trials, business developments to investment due diligence, our clients can make better business decisions on our fully integrated one-stop intelligence center platform. | GlobalData’s Construction portfolio offers insights across the entire global construction market, from market-sizing, companies, construction innovations, risks, regulatory developments, M&A, and financial transactions, to projects and project contacts. Our connected Construction Intelligence offers the most comprehensive coverage of construction projects available, tracking new construction projects totaling over US$70tn globally from announcement to completion, by sector, stage, scope, and more. Our industry leading portfolio of brands include Cranes Today, Tunnels & Tunnelling, and World Construction Network amongst others, and have informed the construction landscape since 1969.
Evaluate
Evaluate radically transforms your confidence in strategic portfolio decisions. We are the leading provider of commercial intelligence and predictive analytics for the global pharmaceutical industry. We work with the world’s largest pharmaceutical corporations, financial services firms, management consultancies and service providers, as well as a wide range of innovative biotech and medtech companies. From an overview of the broader market to a detailed product or company analysis, Evaluate’s integrated platform is designed to take you from exploration to full understanding as quickly and accurately as possible. We help you: – Identify competitor developments and likely time to market – Forecast patient populations and product sales for a potential lead asset – Undertake NPV assessments based on modelling discounted cash flows – Manage clinical trial costing Evaluate offers a pharmaceutical Consulting & Analytics service designed to help clients address unique scientific, clinical and commercial challenges. Our pharmaceutical consulting services provide insight into: – Market Analysis & Competitor Intelligence – Corporate Strategy & Franchise Planning – Market Expansion & Forecasting – Mergers & Acquisition – New Product Development – Market Access and Pricing – Commercialization Evaluate is now a Norstella company: an organization that helps to ease and accelerate patient access to life-changing therapies. | Evaluate radically transforms your confidence in strategic portfolio decisions. In biopharma, making the right decisions has an incredible impact on patients’ lives. Making those decisions requires a deep understanding of your market; from identifying opportunities and mitigating risk to evaluating assets and pipelines. Evaluate provides a complete and dynamic view of the pharmaceutical market, with innovative solutions that bring together technology, real world data, and deep expertise to help you make portfolio decisions that drive growth. | Evaluate provides trusted commercial intelligence and forecasting models for the pharmaceutical industry. We help our clients to refine and transform their understanding of the past, present and future of the global biopharma market to drive better decisions. Evaluate’s solutions give you the time and confidence to turn understanding into insight, and insight into action. Market Sizing & Forecasting: Evaluate’s suite of forecasting solutions enables you to make confident investment, partnering, and commercial decisions. Gold-standard consensus forecasts provide an unmatched view into your markets, while custom forecast models, and proprietary analogs enable you to develop informed forecasts on your key assets. The result? A comprehensive view of the market – and your place in it. Business Development & Licensing: Every deal is different and requires a clear view of potential partners, comparable deals, and market potential. To support you, we go beyond asset assessment. Our solutions provide a systematic approach to enable you to compare candidates based on commercial, clinical, and scientific criteria such as market novelty, potential revenue, competitive intensity, and partner suitability. Portfolio Optimization & Asset Strategy: In an ever-evolving market landscape, you must understand the intricacies of clinical and commercial differentiation. Our comprehensive suite of solutions and insights give you the competitive edge you need to navigate the market’s complexities, optimize your pipeline, develop comprehensive scenario planning, and prioritize the right indications. Competitive Intelligence: For biotech and pharma companies alike, a comprehensive view of the competitive landscape is vital. Evaluate’s blend of data-driven solutions and expert analysis provide real-time tracking, analysis, and strategic intelligence to support decision-making processes across drug development, manufacturing, and market competition. So nothing need take you by surprise. Consulting & Analytics: Evaluate’s custom analytics team help you to address unique commercial challenges. We answer key asset, portfolio, and corporate strategy-related questions, powered by the combined resources of Norstella. With access to extensive data assets and experience across therapy areas and modalities, we partner with you to provide the answers you need to drive success.